TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Interaction Details
01. General Information
Pair Name Piperlongumine, Oxaliplatin
Phytochemical Name Piperlongumine (PubChem CID: 637858 )
Anticancer drug Name Oxaliplatin (PubChem CID: 9887053 )
Structure of
Phytochemical
2D-img
Download
2D MOL 3D MOL
Structure of
Anticancer Drug
2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 419
Pair Name Piperlongumine, Oxaliplatin
Disease Info [ICD-11: 2B72] Gastric cancer Investigative
Biological Phenomena Induction-->DNA damage
Gene Regulation Up-regulation Expression H2AX hsa3014
Up-regulation Phosphorylation MAPK14 hsa1432
Up-regulation Phosphorylation MAPK8 hsa5599
In Vitro Model SGC-7901 Human papillomavirus-related cervical adenocarcinoma Homo sapiens (Human) CVCL_0520
BGC-823 Human papillomavirus-related cervical adenocarcinoma Homo sapiens (Human) CVCL_3360
In Vivo Model HCT116 cells (5×10⁶ cells in 100 μl PBS) were harvested and injected subcutaneously into the right flanks of the mice. Next, the mice were divided into four experimental groups on randomization and blinding, with four mice in each group.
Result Piperlongumine significantly enhanced oxaliplatin-induced growth inhibition of these cells and that TrxR1 activity is involved in their synergistic effect both in vitro and in vivo. These data suggest that PL and oxaliplatin combination treatment of gastric cancer may be more effective than oxaliplatin alone.
Combination Pair ID: 618
Pair Name Piperlongumine, Oxaliplatin
Disease Info [ICD-11: 2B90] Colon cancer Investigative
Biological Phenomena Induction-->Oxidative Stress
Gene Regulation Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Up-regulation Activity CASP3 hsa836
In Vitro Model HCT 116 Colon carcinoma Homo sapiens (Human) CVCL_0291
LoVo Colon adenocarcinoma Homo sapiens (Human) CVCL_0399
In Vivo Model For a xenograft model, HCT-116 cells (1×10⁷ in 150 uL PBS) were subcutaneously injected into the right flank of five-week-old female athymic BALB/c nu/nu mice.
Result This study provides a novel combination therapy for colorectal cancer, and reveals that manipulating ROS production might constitute an effective tool for developing novel treatments in colorectal cancer.
03. Reference
No. Title Href
1 Piperlongumine potentiates the antitumor efficacy of oxaliplatin through ROS induction in gastric cancer cells. Cell Oncol (Dordr). 2019;42(6):847-860. doi:10.1007/s13402-019-00471-x Click
2 The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress. Cell Death Dis. 2019 Aug 8;10(8):600. doi: 10.1038/s41419-019-1824-6. Click
It has been 48258 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP